FDA Approves QULIPTA , the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine
ABBVie today announced that the U.S. Food and Drug Administration approved QULIPTA™ for the preventive treatment of episodic migraine in adults. 1 QULIPTA is the first and only oral calcitonin gene-related peptide receptor antagonist specifically developed for the preventive treatment of migraine. 2 Experience the interactive Multichannel News Release here: "Millions of people living with migraine often lose days ...